Study of the Effect of Intravenous AVE0005 (VEGF Trap) in Advanced Ovarian Cancer Patients With Recurrent Symptomatic Malignant Ascites
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00327444 |
Recruitment Status :
Completed
First Posted : May 18, 2006
Results First Posted : January 1, 2013
Last Update Posted : January 1, 2013
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
This study was designed to characterize the effect of aflibercept in participants with advanced chemoresistant ovarian cancer.
Primary objective: Compare the effect of aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®) to placebo treatment on repeat paracentesis in symptomatic malignant ascites in participants with advanced ovarian cancer
Secondary objectives: Safety, tolerability, paracentesis-related parameters, participant-reported outcome.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Ovarian Neoplasms Ascites | Drug: aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®) Drug: Placebo | Phase 2 Phase 3 |
The study included:
- A Thirty (30)-day screening phase
- The double blind treatment period for a minimum of 60 days. Day 1 of the double-blind treatment period was defined as the date of the qualifying paracentesis (ie, withdrawal of >= 1 Liter of ascitic fluid). Participants were randomized after adequate recovery from the qualifying paracentesis (The first dose was administered on Day 1 or Day 2).
- The optional open-label extension (until treatment discontinuation criteria were met)
- A posttreatment follow-up phase lasting 60 days.
Criteria for discontinuation included:
- Participant or his legally authorized representative request discontinuation
- In the Investigator's opinion, continuation of treatment would be detrimental to the participant's well being, such as disease progression, unacceptable toxicity, noncompliance, or logistical considerations
- Sponsor request
- Intercurrent illness that prevented further administration of investigational product(IP)
- More than 2 IP dose reductions
- Unacceptable adverse events (AE) not manageable by symptomatic therapy, dose delay, or dose modification
- Arterial thromboembolic events, including cerebrovascular accidents, myocardial infarctions, transient ischemic attacks, new onset or worsening of preexisting angina
- Radiographic evidence of intestinal obstruction (for example, dilated loops of bowel accompanied by air-fluid levels) or gastrointestinal perforation (for example, presence of extraluminal gas) requiring surgical intervention
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 58 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Double (Participant, Investigator) |
Primary Purpose: | Treatment |
Official Title: | A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-arm Study of the Effect of Intravenous Aflibercept Administered Every 2 Weeks in Advanced Ovarian Cancer Patients With Recurrent Symptomatic Malignant Ascites |
Study Start Date : | July 2006 |
Actual Primary Completion Date : | October 2009 |
Actual Study Completion Date : | October 2009 |
Arm | Intervention/treatment |
---|---|
Placebo Comparator: Placebo
Participants with advanced ovarian cancer administered placebo in the double-blind (DB) period. In the open-label (OL) period, participants had the option to receive aflibercept or be withdrawn from the study. |
Drug: Placebo
Placebo was administered intravenously (IV) over 1 hour once every 2 weeks in the DB period. Drug: aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®) 4.0 mg/kg aflibercept was administered intravenously (IV) over 1 hour once every 2 weeks in the OL period. |
Experimental: Aflibercept
Participants with advanced ovarian cancer administered aflibercept in the double-blind (DB) period. In the open-label (OL) period, participants had the option to continue to receive aflibercept or be withdrawn from the study. |
Drug: aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)
4.0 mg/kg aflibercept was administered intravenously (IV) over 1 hour once every 2 weeks in the DB period. Drug: aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®) 4.0 mg/kg aflibercept was administered intravenously (IV) over 1 hour once every 2 weeks in the OL period. |
- Time to Repeat Paracentesis (TRP) [ Time Frame: From Day 1 up to 6 months from randomization ]
TRP was defined as the number of days between the date of randomization and the date of the first post-randomization paracentesis.
For participants who did not undergo a postrandomization paracentesis on study, TRP was calculated from randomization to the end of the double-blind treatment period.
- Area Under the Curve (AUC) for Participant Assessed Ascites Impact Measure (AIM) [ Time Frame: From Day 1 up to 60 days from randomization to the first postrandomization paracentesis ]
AIM 4 symptoms (abdominal discomfort, abdominal bloating, abdominal pain, and ability to move normally) are scored from 0 to 5, where higher scores represent worst outcomes. An AIM total score ranges from 0-20.
A plot for (The AIM questionnaire total score - Baseline score) versus time were generated. AIM AUC represents the overall improvement (scored positive) if the area is below the baseline value or worsening (scored negative) if the area is above the baseline. AIM AUC for a participant is the sum of individual areas representing improvement (+) or worsening (-).
- 60-Day Frequency of Paracentesis (FOP) [ Time Frame: From Day 1 up to 60 days from randomization ]60-Day FOP was defined as the total number of paracenteses performed within the first 60 days after randomization during the double blind treatment period.
- Plasma Levels of Free and VEGF-bound Aflibercept [ Time Frame: Following every biweekly treatment administration up to 60 days after treatment discontinuation ]
Free aflibercept and VEGF-bound aflibercept plasma concentrations were measured by separate enzyme-linked immunosorbent assay (ELISA). The limit of quantitation of free aflibercept was 15.6 ng/mL, and of VEGF-bound aflibercept was 43.9 ng/mL.
Peak free aflibercept was estimated at the end of Cycle 1 (C1) administration. The median free and VEGF-bound trough concentrations were determined for each participant beyond Cycle 3 (C3), then mean values were estimated from these median values.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Participants who met the following criteria were eligible to participate in this study.
Inclusion Criteria:
- Advanced ovarian epithelial cancer, treated with paracentesis
- Platinum-resistant, and topotecan-resistant and/or liposomal doxorubicin-resistant disease;
- Eastern Cooperative Oncology Group (ECOG) performance status =< 2.
Exclusion Criteria:
- Pseudomyxoma peritonei or peritoneal mesothelioma;
- Transudative ascites;
- Peritoneovenous or other shunt placed for malignant ascites management;
- Recent (<6 months) cardiovascular event (pulmonary embolus, myocardial infarction, stroke) or gastrointestinal disease (ulcer, hepatic cirrhosis);
- Known brain metastases;
- Uncontrolled hypertension;
- Recent treatment with chemotherapy, surgery or radiotherapy;
- Prior treatment with VEGF or VEGFR inhibitor.
The above information is not intended to contain all considerations relevant to participation in a clinical trial.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00327444
United States, New Jersey | |
Sanofi-Aventis Administrative Office | |
Bridgewater, New Jersey, United States, 08807 | |
Austria | |
Sanofi-Aventis Administrative Office | |
Vienna, Austria | |
Belgium | |
Sanofi-Aventis Administrative Office | |
Diegem, Belgium | |
Canada | |
Sanofi-Aventis Administrative Office | |
Laval, Canada | |
Hungary | |
Sanofi-Aventis Administrative Office | |
Budapest, Hungary | |
India | |
Sanofi-Aventis Administrative Office | |
Mumbai, India | |
Israel | |
Sanofi-Aventis Administrative Office | |
Natanya, Israel | |
Spain | |
Sanofi-Aventis Administrative Office | |
Barcelona, Spain | |
United Kingdom | |
Sanofi-Aventis Administrative Office | |
Guildford Surrey, United Kingdom |
Principal Investigator: | Walter GOTLIEB | Director of Gynecologic Oncology and Colposcopy Associate Professor of Oncology, McGill University - Montreal - Quebec Canada |
Responsible Party: | Sanofi |
ClinicalTrials.gov Identifier: | NCT00327444 |
Other Study ID Numbers: |
EFC6125 EudraCT : 2005-005026-31 AVE0005A /3001 |
First Posted: | May 18, 2006 Key Record Dates |
Results First Posted: | January 1, 2013 |
Last Update Posted: | January 1, 2013 |
Last Verified: | July 2011 |
Ovarian neoplasm Ascites Angiogenesis inhibitor Vascular Endothelial Growth Factor A Recombinant fusion protein |
Ovarian Neoplasms Ascites Neoplasms Endocrine Gland Neoplasms Neoplasms by Site Ovarian Diseases Adnexal Diseases Genital Diseases, Female Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Urogenital Diseases Genital Neoplasms, Female |
Urogenital Neoplasms Genital Diseases Endocrine System Diseases Gonadal Disorders Pathologic Processes Aflibercept Angiogenesis Inhibitors Angiogenesis Modulating Agents Growth Substances Physiological Effects of Drugs Growth Inhibitors Antineoplastic Agents |